MD

LOXO-101 receives breakthrough therapy designation from FDA for solid tumors with NTRK gene fusions

Loxo Oncology  announced in a press release that the FDA has granted breakthrough therapy designation to LOXO-101 for the treatment of unresectable or metastatic solid tumors with neurotrophic tyrosine receptor kinase gene fusions. This [...]

By |2020-02-21T14:56:38-05:00July 21st, 2016|News, Research|

GIST Day of Learning: Education and Support for Area GISTers

The Life Raft Group kicked off its 2016 GIST Day of Learning (GDOL) series this spring with events from coast to coast. GDOLs are free, one-day programs that provide both education and support for the GIST [...]

By |2019-06-03T16:19:13-04:00June 10th, 2016|GIST Education, Newsletter|
Go to Top